trending Market Intelligence /marketintelligence/en/news-insights/trending/Pru8nwCo7Uhcp1cCiRODJA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Wuhan General Group undertaking reorganization to advance growth strategies

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Wuhan General Group undertaking reorganization to advance growth strategies

Wuhan General Group Inc. is undertaking a strategic reorganization to capitalize on the medical marijuana and psilocybin mushroom industries.

The move aims to align the business with the company's three primary growth strategies: optimizing the core value, boosting health and well-being product lines, and accelerating the distribution of new business models.

Wuhan noted that Jeffrey Robinson replaced Ramy Kamaneh as CEO, while Kamaneh transitioned to the role of CFO at the company.

In June, Wuhan acquired 49% of assets held by Biodelta Nutraceuticals Ltd., a Cape Town, South Africa-based manufacturer of CBD products, for about $1.6 million in cash.

The assets, which included land, buildings, infrastructure and specialized greenhouse and drying ovens, became part of Wuhan's operational facility in South Africa.

Robinson noted that the joint venture partnership between Wuhan and Biodelta was a catalyst for the company's reorganization.

Wuhan General develops and commercializes a range of CBD-based products through its subsidiary MJ MedTech.